Risk factors for vascular complications and treatment patterns at diagnosis of 2389 <scp>PV</scp> and <scp>ET</scp> patients: Real‐world data from the Swedish <scp>MPN</scp> Registry

Khadija Abdulkarim(Sahlgrenska University Hospital), Björn Andréasson(NU Hospital Group), Jan Samuelsson(Karolinska University Hospital), Peter Johansson(Linköping University)

European Journal Of Haematology

March 2, 2017

10.1111/ejh.12873

Cited by 26

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

|Blood|1998|306

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194